Company Information

Company Profile

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Contact Information

Investor Relations
Aurinia@westwicke.com

Company Contact
Aurinia Pharmaceuticals Inc.
#1203-4464 Markham Street
Victoria, BC V8Z 7X8